Vascular Responses at Proximal and Distal Edges of Paclitaxel-Eluting Stents: Serial Intravascular Ultrasound Analysis From the TAXUS II Trial

Background—On the basis of brachytherapy experience, edge stenosis has been raised as a potential limitation for drug-eluting stents. We used serial intravascular ultrasound (IVUS) to prospectively analyze vessel responses in adjacent reference segments after implantation of polymer-controlled paclitaxel-eluting stents. Methods and Results—TAXUS II was a randomized, double-blind trial with 2 consecutive patient cohorts that compared slow-release (SR) and moderate-release (MR) paclitaxel-eluting stents with control bare metal stents (BMS). By protocol, all patients had postprocedure and 6-month follow-up IVUS. Quantitative IVUS analysis was performed by an independent core laboratory, blinded to treatment allocation, in 5-mm vessel segments immediately proximal and distal to the stent. Serial IVUS was available for 106 SR, 107 MR, and 214 BMS patients. For all 3 groups, a significant decrease in proximal-edge lumen area was observed at 6 months. The decrease was comparable (by ANOVA, P =0.194) for patients in the SR (−0.54±2.1 mm2) and MR (−0.88±1.9 mm2) groups compared with the BMS (−1.02±1.9 mm2) group. For the distal edge, a significant decrease in lumen area was only observed with BMS (−0.91±2.0 mm2, P <0.0001); this decrease was significantly attenuated with SR (0.08±2.0 mm2) and MR (−0.19±1.7 mm2) stents (P <0.0001 by ANOVA). Negative vessel remodeling was observed at the proximal (−0.48±2.2 mm2, P =0.011) but not the distal edges of BMS and at neither edge of SR or MR stents. Conclusions—The marked reduction in in-stent restenosis with SR or MR stents is not associated with increased edge stenosis at 6-month follow-up IVUS. In fact, compared with BMS, there is instead a significant reduction in late lumen loss at the distal edge with TAXUS stents.

[1]  S. Silber,et al.  Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions , 2003, Circulation.

[2]  N. Weissman,et al.  Paclitaxel Coating Reduces In-Stent Intimal Hyperplasia in Human Coronary Arteries: A Serial Volumetric Intravascular Ultrasound Analysis From the ASian Paclitaxel-Eluting Stent Clinical Trial (ASPECT) , 2003, Circulation.

[3]  Mary E. Russell,et al.  TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions , 2003, Circulation.

[4]  P. Serruys,et al.  Persistent Inhibition of Neointimal Hyperplasia After Sirolimus-Eluting Stent Implantation: Long-Term (Up to 2 Years) Clinical, Angiographic, and Intravascular Ultrasound Follow-Up , 2002, Circulation.

[5]  B. Davis,et al.  Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial , 2002, Circulation.

[6]  A. Yeung,et al.  Use of localised intracoronary β radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial , 2002, The Lancet.

[7]  P. Levendag,et al.  Angiographical Follow-Up After Radioactive “Cold Ends” Stent Implantation: A Multicenter Trial , 2002, Circulation.

[8]  R. Virmani,et al.  Histopathologic Alterations after Endovascular Radiation and Antiproliferative Stents: Similarities and Differences , 2002, Herz.

[9]  Levon M Khachigian,et al.  Coronary In-stent Restenosis: Current Status and Future Strategies , 2022 .

[10]  J. Vinten-johansen,et al.  Perivascular Responses after Angioplasty Which May Contribute to Postangioplasty Restenosis , 2001, Annals of the New York Academy of Sciences.

[11]  P. Serruys,et al.  The TRAPIST Study. A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound. , 2001, European heart journal.

[12]  Nico Bruining,et al.  A novel approach to quantitative analysis of intra vascular ultrasound images , 2001, Computers in Cardiology 2001. Vol.28 (Cat. No.01CH37287).

[13]  N. Weissman,et al.  Extent and distribution of in-stent intimal hyperplasia and edge effect in a non-radiation stent population. , 2001, The American journal of cardiology.

[14]  P. Fitzgerald,et al.  Novel Drug-Delivery Stent: Intravascular Ultrasound Observations From the First Human Experience With the QP2-Eluting Polymer Stent System , 2001, Circulation.

[15]  P. Teirstein,et al.  Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. , 2001, The New England journal of medicine.

[16]  Renu Virmani,et al.  Experimental evaluation of a short transitional edge protection balloon for intracoronary stent deployment , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[17]  A. Colombo,et al.  Edge Restenosis After Implantation of High Activity 32P Radioactive β-Emitting Stents , 2000 .

[18]  P. Serruys,et al.  I like the candy, I hate the wrapper: the (32)P radioactive stent. , 2000, Circulation.

[19]  Patrick W. Serruys,et al.  Handbook of Coronary Stents , 1997 .

[20]  E. Regar,et al.  Serial follow-up after optimized ultrasound-guided deployment of Palmaz-Schatz stents. In-stent neointimal proliferation without significant reference segment response. , 1997, Circulation.

[21]  M. Leon,et al.  Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. , 1996, Circulation.

[22]  Ousa,et al.  A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .

[23]  S. Silber,et al.  THE BOSTON SCIENTIFIC ANTIPROLIFERATIVE , PACLITAXEL ELUTING STENTS ( TAXUS ) , 2001 .

[24]  S. Parikh,et al.  Edge restenosis after implantation of high activity (32)P radioactive beta-emitting stents. , 2001, Circulation.

[25]  C. Mario,et al.  Edge restenosis after implantation of high activity (32)P radioactive beta-emitting stents. , 2000, Circulation.